Access Pharmaceuticals of Texas revealed plans for a clinical trial of its solid tumor cancer drug, ProLindac, in China. The trial will be conducted by Access Pharma’s China partner, Aosaikang Medicinal Group (ASK), a company that is also responsible for manufacturing scale-up of ProLindac. Access plans to use the China trial, along with a similar one conducted in South Korea by JCOM of Seoul, to help gain regulatory approval of ProLindac in the US and Europe. More details...

Stock Symbol: (OTCBB: ACCP)